StockData
Cingulate Inc. logo

Cingulate Inc. (CING) stock

CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.75−0.55 (-12.79%)

Close on Nov 16, 2026Market cap $54.53MP/E –Yield –

Cingulate operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cingulate's operating income for the twelve months ending Jun 30, 2026 was -$24.92M. For fiscal 2025 it was -$19.94M. The highest annual figure on record is -$7.08M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.94M–
FY2024Dec 31, 2024-$15.64M–
FY2023Dec 31, 2023-$22.76M–
FY2022Dec 31, 2022-$17.50M–
FY2021Dec 31, 2021-$20.68M–
FY2020Dec 31, 2020-$7.08M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.41M–
Q1 FY2026Mar 31, 2026-$7.92M–
Q4 FY2025Dec 31, 2025-$5.59M–
Q3 FY2025Sep 30, 2025-$6.00M–
Q2 FY2025Jun 30, 2025-$4.65M–
Q1 FY2025Mar 31, 2025-$3.71M–
Q4 FY2024Dec 31, 2024-$6.21M–
Q1 FY2024Mar 31, 2024-$2.95M–
Q4 FY2023Dec 31, 2023-$6.80M–
Q3 FY2023Sep 30, 2023-$5.75M–
Q2 FY2023Jun 30, 2023-$6.36M–
Q1 FY2023Mar 31, 2023-$3.85M–
Q4 FY2022Dec 31, 2022-$4.48M–
Q3 FY2022Sep 30, 2022-$3.97M–
Q2 FY2022Jun 30, 2022-$4.05M–
Q1 FY2022Mar 31, 2022-$5.01M–
Q4 FY2021Dec 31, 2021-$2.65M–
Q3 FY2021Sep 30, 2021-$15.28M–
Q2 FY2021Jun 30, 2021-$1.42M–
Q1 FY2021Mar 31, 2021-$1.33M–

More Cingulate figures

See a number that looks wrong?